Dr. Andrew Holzman to Participate in FDA Trial

Andrew Holzman, MD, board certified ophthalmologist, has had his McLean, Va., practice site sanctioned by the FDA as a test site for the cross-linking treatment of kerataconus.

Advertisement

Cross-linking, currently available in Europe, is a procedure conducted under topical anesthesia designed to increase collagen production in order to combat the effects of kerataconus.

Dr. Holzman earned his medical degree from the University of Miami School of Medicine and completed his residency at George Washington University in Washington, DC. He conducted his fellowship at the University of Pittsburgh Medical Center.

More Articles on Ophthalmology:
$2M in NIH Funds Helps Researchers Combat Diabetic Related Vision Loss
Northwest Dry Eye Center Opens in Washington, Offers New Treatment
$3.6M in Series A Funding Goes to MacuLogix

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.